Business
EQT Life Sciences to exit minority stake in Tubulis via sale to Gilead Sciences for up to USD 5.0 billion
EQT Life Sciences is pleased to announce that the LSP 7 fund ("EQT Life Sciences") has exited its minority stake in Tubulis (the "Company"), a Germany-based, clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs), through a sale to Gilead Sciences [Nasdaq: GILD].
About this update from Eqt Corporation
[{"type":"list","items":[{"val":[{"type":"text","content":"Gilead Sciences has entered into a definitive agreement to acquire Tubulis, a private Germany-based, clinical-stage biotechnology company","length":137,"tagName":"p"}]},{"val":[{"type":"text","content":"EQT Life Sciences led the Series B2 financing of Tubulis in March 2024, and has since suppEQTorted the Company at board level in its growth to a leading global clinical-stage ADC company","length":186,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":323,"olType":false},{"type":"text","content":"AMSTERDAM, April 7, 2026 /PRNewswire/ -- EQT Life Sciences is pleased to announce that the LSP 7 fund ("EQT Life Sciences") has exited its minority stake in Tubulis (the "Company"), a Germany-based, clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs), through a sale to Gilead Sciences [Nasdaq: GILD].","length":365,"tagName":"p"},{"type":"text","content":"Tubulis' lead asset, TUB-040, a NaPi2b-directed topoisomerase-I inhibitor (TOPO1i) ADC, is currently in Phase 1b/2 development for platinum-resistant ovarian cancer and non-small cell lung cancer (NSCLC). Gilead will also acquire TUB-030, a 5T4 targeted ADC, which has demonstrated promising initial clinical data across various solid tumor types as well as a next-generation ADC platform and a promising early pipeline.","length":424,"tagName":"p"},{"type":"text","content":"EQT Life Sciences co-led the oversubscribed Series B2 financing in 2024, and since then, has helped Tubulis advance into a clinical-stage oncology player, progress its pipeline, and build a differentiated antibody-drug conjugate platform targeting solid tumors. Working closely with the management team, EQT Life Sciences supported this journey through active board involvement and strategic guidance, helping position Tubulis as a partner of choice in a rapidly growing and highly competitive field.","length":500,"tagName":"p"},{"type":"text","content":"The transaction represents a strong and strategic outcome for LSP 7 and its co-investors, and reflects EQT Life Sciences' ambition to back outstanding science early, helping companies scale through critical inflection points into globally relevant businesses. Today's announcement also underscores the continued demand for innovative oncology platforms that can...